Compare ASPN & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASPN | STTK |
|---|---|---|
| Founded | 2001 | 2016 |
| Country | United States | United States |
| Employees | 854 | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.3M | 275.9M |
| IPO Year | 2011 | 2020 |
| Metric | ASPN | STTK |
|---|---|---|
| Price | $3.26 | $5.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $4.25 | ★ $7.60 |
| AVG Volume (30 Days) | ★ 1.3M | 674.5K |
| Earning Date | 05-07-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $271,103,000.00 | $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $38.83 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.30 | $0.69 |
| 52 Week High | $9.78 | $6.81 |
| Indicator | ASPN | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 48.57 | 62.52 |
| Support Level | $2.92 | $1.85 |
| Resistance Level | $3.80 | N/A |
| Average True Range (ATR) | 0.21 | 0.37 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 32.67 | 36.01 |
Aspen Aerogels Inc is an aerogel technology company that designs, develops, and manufactures high-performance aerogel insulation used in the energy industrial and sustainable insulation markets. The company also conducts research and development related to aerogel technology, supported by funding from several agencies of the United States of America government and other institutions in the form of research and development contracts. It is engaged in two operating segment Energy Industrial and Thermal Barrier. Geographically, it operates in the U.S. and also has a presence in other International countries. It generates the majority of its revenue from the Thermal Barrier segment and the United States market. Some of its products include Pyrogel XTE, Cryogel Z, Spaceloft Subsea, and others.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.